The company provided a trading update for the year ending 31 March 2017, indicating that results will be in line with market expectations, with revenues of £14.25m and adjusted pre-tax profits of £1.1m. We introduce forecasts for FY 2018, which includes first commercial sales of Malaria tests but, pending the outcome and clarification of ongoing discussions with Immunodiagnostic Systems (IDS), we have assumed no revenues for Allersys. We maintain a 28p price target, which implies
25 Apr 2017
In-line trading update and FY 2018 estimates
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
In-line trading update and FY 2018 estimates
Cambridge Nutritional Sciences PLC (CNSL:LON) | 3.1 0 0.0% | Mkt Cap: 7.38m
- Published:
25 Apr 2017 -
Author:
Mark Brewer | Cavendish Research -
Pages:
12
The company provided a trading update for the year ending 31 March 2017, indicating that results will be in line with market expectations, with revenues of £14.25m and adjusted pre-tax profits of £1.1m. We introduce forecasts for FY 2018, which includes first commercial sales of Malaria tests but, pending the outcome and clarification of ongoing discussions with Immunodiagnostic Systems (IDS), we have assumed no revenues for Allersys. We maintain a 28p price target, which implies